[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"molecular-sequence-variation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:molecular-sequence-variation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,79,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100467248","molecular-diagnosis-of-systemic-autoinflammatory-diseases-100467248",false,"NCT05364294","Molecular Diagnosis of Systemic Autoinflammatory Diseases","SAIDiag","Inclusion Criteria:\n\n* A patient presenting with a clinical and biological aseptic inflammatory syndrome associating one or more of the following signs: spontaneously resolving fever, abdominal (pain, diarrhea), locomotor (arthralgia, myalgia), thoracic (pain, pericarditis), cutaneous, sensory (uveitis, deafness), or renal (amyloidosis) involvement.\n\nExclusion Criteria:\n\n* Adult subject to legal protection measures (guardianship, curatorship, safeguard of justice).",true,"ALL","1 Week","120 Years",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","Systemic autoinflammatory diseases (SAIDs) are a set of rare clinically and genetically heterogeneous conditions. The project proposes to identify novel genes and specific signatures in subgroups of patients with SAIDs.",[26,27,28,29,30],"Inflammatory Disease","Genetic Disease","Somatic Mutation","Molecular Sequence Variation","Molecular Pathway Deregulation",[32],"Biomarkers","RECRUITING","2026-03-04",{"date":36,"type":37},"2026-03-05","ACTUAL",{"date":39,"type":37},"2022-05-18",{"date":41,"type":22},"2033-05-02",{"name":43,"class":44},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100432824","diabetic-nephropathy-in-people-with-diabetes-prevalence-and-predictive-factors-100432824","NCT04916132","Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors","Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors","PRIMETIME2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Diagnosis with T2DM according to the American diabetes Association (20)\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2 (maximum six months old)\n* urine-albumin\u002Fcreatinine-ratio (uACR) \\> 700 mg\u002Fg or 24 hours urine albumin \\>700 mg on more than one measurement\n\nExclusion Criteria:\n\n* Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy\n* Factors that increases the risk of complications due to kidney biopsy:\n\n  * Hemoglobin \\\u003C 6 mmol\u002FL\n  * INR \\>1,4 at the time for biopsy\n  * Platelet count \\\u003C 100 x 109\u002Fl\n  * Uncontrolled high blood pressure (defined as systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg)\n  * Only one functioning kidney\n  * Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy\n  * Multiple bilateral kidney cysts\n  * Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy\n  * Unwilling to receive blood transfusion\n  * Unable to lie flat in bed six hours after biopsy\n  * Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines\n* Unable to understand written and oral information\n* Kidney transplant recipient\n* Previous medical kidney biopsy\n* Women who are pregnant or planning to become pregnant before the kidney biopsy is performed\n* Treatment with Marcoumar (all other anticoagulants are accepted)\n* High thromboembolic risk combined with held in anticoagulation therapy according to the report \"Perioperative regulation of antithrombotic treatment\" (PRAB) (22)\n\n  * mechanical heart valve\n  * atrial fibrillation AND CHA2DS2-VASc\\> 5 and\u002For stroke within the last three months\n  * recurrent venous thromboembolism OR venous thromboembolism within the last three months\n  * less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))\n  * less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES))\n  * less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis)\n  * less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG)\n  * less than 3 months after revascularization in individuals with stable CAD (PCI with DES)\n  * less than 3 months after stroke, or Transient Ischemic Attack (TIA)\n* Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy\n\nIf a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.","18 Years",{"count":21,"type":22},"a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.",[58,59,60,61,62,29,63],"Chronic Kidney Diseases","Albuminuria","Diabetic Kidney Disease","Diabetic Nephropathies","Diabetes type2","Kidney Biopsy",[65,66,67],"diabetic nephropaty","precision medicine","kidney biopsy","2025-12-17",{"date":70,"type":37},"2025-12-24",{"date":72,"type":37},"2021-08-10",{"date":74,"type":22},"2043-12-31",{"name":76,"class":77},"Herlev Hospital","OTHER",13,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":99,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100374121","canadian-cancers-with-rare-molecular-alterations-carma---basket-real-world-observational-study-bros-100374121","NCT04151342","CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)","CARMA-BROS","Inclusion Criteria:\n\n* Patients ≥ 18 years at cancer diagnosis\n* Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations\n* Accessible\u002Favailable molecular testing reports\u002Fdocumentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \\[PCR\\] based next generation sequencing \\[NGS\\], immunohistochemistry \\[IHC\\], fluorescence in situ hybridization \\[FISH\\], liquid biopsy)\n* Canadian resident received follow-up for cancer care in Canada or is currently receiving\u002Fplanning follow-up for cancer care to occur in Canada at time of enrollment\n\nExclusion Criteria:\n\n* Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent",{"count":87,"type":22},5500,"This study will collect data on Canadian cancer patients that have uncommon\u002Frare changes in their tumours, such as alterations\u002Frearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.",[90,91,92,93,29,94,95,96,97,98],"Cancer","Malignancies Multiple","Malignant Solid Tumor","Cancer, Therapy-Related","Genetic Alteration","Gene Fusion","Receptor Tyrosine Kinase Gene Mutation","RTK Family Gene Mutation","Ras (Kras or Nras) Gene Mutation",[100,101,102,103,104,105,106,107,108],"observational study","cancer","cancer therapies","molecular alterations","real-world evidence","real-world data","tyrosine kinase inhibitors","ambispective","ras GTPase inhibitors","2025-11-25",{"date":111,"type":37},"2025-12-03",{"date":113,"type":37},"2020-01-17",{"date":115,"type":22},"2029-12",{"name":117,"class":77},"University Health Network, Toronto",27,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100533518","phase-3-other-oncogene-mutations-for-anti-egfr-efficacy-in-patients-with-left-sided-ras-wild-type-metastatic-colorectal-cancer-100533518","NCT06226857","Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","Predictive Value of Other Oncogene Mutations for Anti-EGFR Monoclonal Antibodies Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer: Multicenter Randomized Phase III Trial","CRC01","Inclusion Criteria:\n\n1. Informed consent signed before commencing any procedures related to the clinical trial.\n2. Age ≥18 years.\n3. ECOG status 0-2.\n4. Life expectancy greater than 12 weeks as assessed by the investigator.\n5. Verified diagnosis of colorectal adenocarcinoma (C18.5, C19, C20).\n6. Metastatic unresectable form of the disease that has not previously received any systemic therapy for the metastatic process (previous neo-\u002Fadjuvant therapy completed at least 6 months before the detection of metastases is allowed).\n7. Left-sided localization of the primary tumor (from the splenic flexure of the colon inclusive).\n8. Verified wild type KRAS, NRAS determined from tumor tissue.\n9. Satisfactory function of hematopoiesis and internal organs:\n\n   * absolute number of neutrophils ≥ 1.5×10 9 \u002Fl;\n   * platelets ≥ 100×10 9 \u002Fl;\n   * hemoglobin ≥ 90 g\u002Fl.\n   * creatinine clearance above 50 ml\u002Fmin;\n   * total bilirubin \\\u003C1.5 X the upper limit of normal;\n   * ALT or AST \\>5 X the upper limit of normal in the presence of liver metastases or \\>2.5 X the upper limit of normal in the absence of liver metastases.\n10. Availability of a sufficient amount of tumor material for molecular genetic research. Tumor material must be collected no more than 24 months before inclusion in the study.\n\nExclusion Criteria:\n\n1. Previous systemic therapy for metastatic disease.\n2. Presence of KRAS\u002FNRAS\u002FV600E mutations (except for unknown BRAF status).\n3. Uncertain KRAS\u002FNRAS status\n4. The presence of any other malignant tumor, with the exception of radically treated basal cell carcinoma, cervical cancer in situ, currently or within 5 years before inclusion in the study. Pregnant and lactating women, as well as planning pregnancy during the period of therapy in a clinical trial and 6 months after the end of therapy.\n5. HIV infection, active hepatitis B, active hepatitis C.\n6. Complicated primary tumor, requiring urgent surgical intervention. After it is eliminated, the patient can participate in the study.\n7. The presence of a disease or condition that, in the opinion of the investigator, prevents the patient from participating in the study.\n8. Impossibility of organizing central venous access.","99 Years",{"count":129,"type":22},355,"INTERVENTIONAL",[132],"PHASE3","Patients meeting the inclusion criteria will be randomized 1:1 into Cohort A (n ≈ 177) or Cohort BC (n ≈ 177). Cohort A is the control: patients receive combination chemotherapy with FOLFOX plus anti-EGFR therapy (panitumumab or cetuximab) based on RAS\u002FBRAF wild-type data, according to clinical guidelines.\n\nThe BC cohort begins FOLFOX chemotherapy and simultaneously undergoes extensive molecular genetic profiling. Further, the BC cohort, depending on the profile, is divided into cohort B - patients without changes in alternative oncogenes, and cohort C - with changes in alternative oncogenes. The expected cohort ratio is 3:1 (\\~120 and \\~40 patients). Cohort B begins to receive anti-EGFR therapy in addition to chemotherapy, and the potentially resistant cohort C continues to receive chemotherapy alone or begins to receive bevacizumab if there are no contraindications.",[135,136,29],"Colorectal Neoplasms","Chemotherapy Effect","2024-01-25",{"date":139,"type":37},"2024-01-29",{"date":141,"type":37},"2024-01-17",{"date":143,"type":22},"2027-12-31",{"name":145,"class":44},"City Clinical Oncology Hospital No 1",3]